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Post-operative Analgesia in Opioid Dependent Patients: Comparison of 
Intravenous Morphine and Sublingual Buprenorphine 
Shaabanali Alizadeh MD1, Ghafar Ali Mahmoudi MD2, Hassan Solhi MD3,  
Bahman Sadeghi-Sedeh MD4, Reza Behzadi MD5, Amir Mohammad Kazemifar MD6 
 
Abstract 
Background: Acute and chronic pain is prevalent in patients with opioid dependence. Lack of knowledge 
concerning the complex relationship between pain, opioid use, and withdrawal syndrome can account for the 
barriers encountered for pain management. This study was designed to evaluate the efficacy of sublingual 
(SL) buprenorphine for post-operative analgesia, compared with intravenous (IV) morphine. 
Methods: A total of 68 patients, aged 20-60 years were randomly selected from whom had been underwent 
laparotomy due to acute abdomen in a University Teaching Hospital in Arak, Iran, and were also opioid 
(opium or heroin) abuser according to their history. After end of the surgery and patients’ arousal, the 
patients were evaluated for abdominal pain and withdrawal syndrome by visual analog scale (VAS) and 
clinical opioid withdrawal score (COWS), respectively 1, 6, and 24 h after the surgery. They received either 
morphine 5 mg IV or buprenorphine 2 mg SL, 1 h after end of the surgery, and then every 6 h for 24 h. 
Findings: VAS was 4.47 ± 0.73 and 2.67 ± 0.53 at h 6 and 24 in buprenorphine group, respectively. The 
corresponding score was 5.88 ± 0.69 and 4.59 ± 0.74 in morphine group. At the same time, patients in 
buprenorphine experienced less severe withdrawal syndrome. 
Conclusion: The present study confirmed the efficacy of SL buprenorphine as a non-invasive, but effective 
method for management of post-operative pain in opioid dependent patients. Result of this study showed 
that physicians can rely on SL buprenorphine for post-operative analgesia. 
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Introduction 
Pain management in the perioperative setting 
refers to actions before, during, and after a 
procedure that are intended to reduce or eliminate 
post-operative pain before discharge.1 Post-
operative pain continues to be a challenge and is 
often inadequately treated, leading to patient 
anxiety, stress, and dissatisfaction. Inadequately 
treated pain can lead to detrimental physiological 
effects and may also have psychological, 
economic and social adverse effects.2 
Perioperative techniques for post-operative 
pain management include, but are not limited to 
central regional (i.e., neuraxial) opioid analgesia, 
patient controlled analgesia with systemic 
opioids, and peripheral regional analgesic 
techniques.1 The choice mainly depends on the 
strategy favored by the physician and the 
availability of drugs and equipment.2 
Opioids are typically used for the management 
of moderate to severe acute pain, but opioid use is 
limited by the occurrence of a range of side 
effects. Opioids exert their analgesic effects 
primarily through agonistic interactions with µ-
opioid receptors in neurons in the pain pathway, 
which lead to a reduction in neurotransmitter 
release and associated pain.3 The underuse of 
opioid analgesics by health care providers to 
relieve acute pain may be related to attempts to 
balance analgesia against concerns about  
opioid-induced side effects and subsequent 
deleterious repercussions for patient outcome.3 
Clinicians must prescribe and monitor currently 
available opioids based on the best available 
evidence that takes into account the uniqueness of 
each patient’s pain management issues.4 
Some patient groups are at special risk for 
inadequate pain control and require additional 
analgesic considerations, including patients with 
drug abuse.1 The global epidemic of opiate use 
continues to spread, especially in developing 
countries.5 Iran has one of the highest rates of 
opioids abuse in the world.6,7 It is not surprising 
that some patients with acute abdomen also have 
an opioid dependency. They need perioperative 
analgesia too. However, their management may 
complicate with insufficient analgesia, superfluous 
opioid overdose, and withdrawal syndrome. 
Intravenous (IV) or intramuscular (IM) 
administration is more commonly the route of 
choice in critically ill patients with acute pain who 
need opioid analgesia. However, any other route 
with less pain of IM injections and safer than 
direct IV injection is encouraged. 
The present study was designed to evaluate 
the efficacy of sublingual (SL) buprenorphine for 
post-operative analgesia, compared to  
IV morphine. 
Methods 
In this single-blinded randomized clinical trial, 68 
patients, aged 20-60 years were randomly selected 
from whom had been underwent laparotomy due 
to acute abdomen in a university teaching 
hospital in Arak, Iran and were also opioid 
(opium or heroin) abuser according to their 
history. Their induction of anesthesia was similar 
(fentanyl 2-5 µg/kg, midazolam 0.03 mg/kg, 
atracurium 0.5 mg/kg, and nesdonal 3-5 mg/kg). 
After end of the surgery and patients’ arousal, 
the patients were evaluated for abdominal pain 
and withdrawal syndrome by visual analog scale 
(VAS) and clinical opioid withdrawal score 
(COWS), respectively by one of the authors 1, 6, 
and 24 h after the surgery. The patients were 
randomly divided into two groups. The first 
group received morphine 5 mg IV 1 h after the 
end of the surgery, and then every 6 h for 24 h. 
The second group received buprenorphine 2 mg 
SL with the same schedule. Moreover, if any 
patient had VAS score more than 4, or 
complained from pain at any time, he received 
meperidine 25 mg IV. 
The exclusion criteria were the use of any other 
analgesic, sedative, or narcotic before or after the 
surgery, history of head trauma, shock, diabetes 
mellitus, and neurologic diseases. The study had 
been approved by Local Ethical Committee of 
Arak University of Medical Sciences. All the 
studied patients provided informed consent for 
participation to the study. 
The results were analyzed by SPSS software 
(version 16, SPSS Inc., Chicago, IL, USA). 
Differences between the groups were determined 
by two-way repeated measure or chi-square test, 
whatever relevant. Statistical significance was set 
at P < 0.050. 
Results 
68 patients in two equal groups were participated 
in the study. All of them completed the study. All 
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of them except two in the first group, and four in 
the second group were male. Their age was  
30.06 ± 7.95 and 30.68 ± 8.45 years in the first and 
second groups, respectively. The difference was 
not statistically significant (P = 0.757). The 
patients had no significant difference in reason for 
surgery, too. 
The groups had comparable pain severity at the 
start of the study. However, severity of pain reduced 
more prominently in group 2 during the study, 
compared to group 1. Meanwhile, the patients in 
group 2 experienced less severe withdrawal 
syndrome, too. COWS score and VAS score of the 
studied groups was demonstrated in table 1. 
Discussion 
The present study was performed to evaluate the 
efficacy of SL buprenorphine as a non-invasive, but 
effective method for management of post-operative 
pain in opioid-dependent patients. The result of 
this study showed that physicians can rely on SL 
buprenorphine for post-operative analgesia. 
Buprenorphine, synthesized in the late 1960s 
was used as a parenteral analgesic since 1978. 
Buprenorphine is also available in the forms of SL 
tablets or transdermal (TD) patches. It is a partial 
agonist at µ-opioid receptors, an antagonist at 
kappa opioid receptors.8,9 Buprenorphine partial 
mu agonist activity may induce a milder 
withdrawal syndrome than most opioids; thus, 
discontinuing buprenorphine may be easier. 
Buprenorphine is also a κ-receptor antagonist 
and, therefore, less apt to generate dysphoria.10 
Moreover, buprenorphine exhibits ceiling effects 
on respiratory depression due to its intrinsic 
agonist/antagonist effects. This exceptional 
pharmacology offers an enhanced safety profile 
compared other opioids, when used for 
analgesia.10 After SL administration, there is a 
rapid onset of effect (30-60 min) with a peak effect 
at about 90-100 min.11 
According to the Canadian guideline for safe 
and effective use of opioids for chronic non-cancer 
pain, buprenorphine can be used for the treatment 
of opioid addiction in chronic non-cancer pain.12,13 
Furthermore, it can treat opioid-induced 
hyperalgesia, which occur with chronic opioid 
therapy.14 
Though, we did not found any similar studies 
to compare them with the present study, there are 
some studies in the literature about the role of 
buprenorphine in the management of pain. Study 
of Bounes et al. showed that acute and chronic pain 
has a negative impact on the persistence of opioid 
maintenance treatment, particularly in users of 
buprenorphine.15 Neumann et al. have showed that 
SL buprenorphine can be used for the treatment of 
chronic pain in patients with co-existent opioid 
addiction.16 Wang et al. have performed an in-vitro 
study.17 They have suggested that the efficacy of 
morphine, but not buprenorphine for pain control 
is reduced, when the cancers cells have  
P-glycoprotein expression.17 
Hoflich et al. have focused on peripartum pain 
management in opioid-dependent women.18 They 
have concluded that delivering women who are on 
opioid maintenance treatment need more analgesic 
drugs compared to control.18 Study of Przeklasa-
Muszynska and Dobrogowski has confirmed high 
efficacy and good tolerability of TD buprenorphine 
in the treatment of moderate to severe pain that 
cannot be effectively treated with non-opioid 
analgesics.19 Zoltie and Cust have suggested that 
buprenorphine can be used in patients with acute 
abdominal pain without fear of masking the 
diagnosis.20  
Study of Finlay et al. has confirmed the 
superiority of buprenorphine to Pethidine in 
control of pain in ureteric colic.21 Bullingham et al. 
have evaluated the efficacy of buprenorphine and 
paracetamol for pain after minor orthopedic 
surgery with favorable results.22 
 
Table 1. COWS score and VAS score (mean ± SD) of the groups during the study 
Groups VAS score COWS score 
Hour 0 Hour 1 Hour 6 Hour 24 Hour 0 Hour 1 Hour 6 Hour 24 
Group 1 
(mean ± SD) 8.58 ± 0.74 7.14 ± 0.31 5.88 ± 0.69 4.59 ± 0.74 16.94 ± 2.71 2.91 ± 1.33 7.05 ± 1.93 12.52 ± 3.29 
Group 2 
(mean ± SD) 8.70 ± 0.93 7.22 ± 0.47 4.47 ± 0.73 2.67 ± 0.53 18.26 ± 3.40 8.47 ± 2.25 3.02 ± 1.16 7.00 ± 1.68 
P 0.621 0.550 0.001 < 0.001 0.095 < 0.001 < 0.001 < 0.001 
COWS: Clinical opioid withdrawal score; VAS: Visual analogue scale; SD: Standard deviation 
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Study of Conaghan et al. showed that 7 days 
buprenorphine patches plus oral paracetamol are 
non-inferior to co-codamol (codeine plus 
paracetamol) tablets with respect to analgesic 
efficacy in older adults with osteoarthritis pain in 
the hip/knee.23 
The present study also confirmed that SL 
buprenorphine is more effective than parenteral 
morphine in control of post-operative pain in 
opioid-dependent patients. Additionally, it 
produces less sever withdrawal syndrome in them. 
Conclusion 
Patients with opioid addiction who need 
analgesia for various reasons present a 
therapeutic challenge. Increased pain sensitivity 
and the development of opioid tolerance 
complicate the treatment of pain experienced by 
opioid-dependent patients. The present study 
suggests SL buprenorphine for control of pain and 
withdrawal syndrome in opioid-dependent 
patients. 
Conflict of Interests 
The Authors have no conflict of interest.  
Acknowledgements 
The authors would like to appreciate the genuine 
cooperation of the staff of surgery ward of Valie-Asr 
Hospital, Arak during conduction of the study.  
 
References 
1. American Society of Anesthesiologists Task Force on 
Acute Pain Management. Practice guidelines for acute 
pain management in the perioperative setting: an 
updated report by the American Society of 
Anesthesiologists Task Force on Acute Pain 
Management. Anesthesiology 2004; 100(6): 1573-81. 
2. Ahmed A, Latif N, Khan R. Post-operative 
analgesia for major abdominal surgery and its 
effectiveness in a tertiary care hospital. J 
Anaesthesiol Clin Pharmacol 2013; 29(4): 472-7. 
3. Afilalo M, Stegmann JU, Upmalis D. Tapentadol 
immediate release: a new treatment option for acute 
pain management. J Pain Res 2010; 3: 1-9. 
4. Erstad BL, Puntillo K, Gilbert HC, Grap MJ, Li D, 
Medina J, et al. Pain management principles in the 
critically ill. Chest 2009; 135(4): 1075-86. 
5. Solhi H, Salehi B, Alimoradian A, Pazouki S, 
Taghizadeh M, Saleh AM, et al. Beneficial effects 
of Rosmarinus officinalis for treatment of opium 
withdrawal syndrome during addiction treatment 
programs: a clinical trial. Addict Health 2013; 5(3-
4): 90-4. 
6. Ahmadi-Nejad M, Jadidi F, Dehghani M, Divsalar 
K. Studying prevalence and pattern of taking 
narcotic and ecstasy drugs by patients admitted to 
special care centers of Shahid Bahonar Hospital, 
Kerman, Iran. Addict Health 2012; 4(1-2): 57-64. 
7. Solhi H, Sadeghi-Sedeh B, Emami P, Jamalian M, 
Kazemifar AM. Does ingestion of tincture of opium 
notably raise blood alcohol concentration? Addict 
Health 2014; 6(3-4): 100-4. 
8. Naing C, Yeoh PN, Aung K. A meta-analysis of 
efficacy and tolerability of buprenorphine for the 
relief of cancer pain. Springerplus 2014; 3: 87. 
9. Douaihy AB, Kelly TM, Sullivan C. Medications 
for substance use disorders. Soc Work Public 
Health 2013; 28(3-4): 264-78. 
10. Bonhomme J, Shim RS, Gooden R, Tyus D, Rust 
G. Opioid addiction and abuse in primary care 
practice: a comparison of methadone and 
buprenorphine as treatment options. J Natl Med 
Assoc 2012; 104(7-8): 342-50. 
11. Colson J, Helm S, Silverman SM. Office-based 
opioid dependence treatment. Pain Physician 2012; 
15(3 Suppl): ES231-ES236. 
12. Ducharme S, Fraser R, Gill K. Update on the 
clinical use of buprenorphine: in opioid-related 
disorders. Can Fam Physician 2012; 58(1): 37-41. 
13. Vadivelu N, Hines RL. Management of chronic pain 
in the elderly: focus on transdermal buprenorphine. 
Clin Interv Aging 2008; 3(3): 421-30. 
14. Silverman SM. Opioid induced hyperalgesia: 
clinical implications for the pain practitioner. Pain 
Physician 2009; 12(3): 679-84. 
15. Bounes V, Palmaro A, Lapeyre-Mestre M, Roussin 
A. Long-term consequences of acute pain for 
patients under methadone or buprenorphine 
maintenance treatment. Pain Physician 2013; 16(6): 
E739-E747. 
16. Neumann AM, Blondell RD, Jaanimagi U, 
Giambrone AK, Homish GG, Lozano JR, et al. A 
preliminary study comparing methadone and 
buprenorphine in patients with chronic pain and 
coexistent opioid addiction. J Addict Dis 2013; 
32(1): 68-78. 
17. Wang J, Cai B, Huang DX, Yang SD, Guo L. 
Decreased analgesic effect of morphine, but not 
buprenorphine, in patients with advanced  
P-glycoprotein (+) cancers. Pharmacol Rep 2012; 
64(4): 870-7. 
18. Hoflich AS, Langer M, Jagsch R, Bawert A, 
Winklbaur B, Fischer G, et al. Peripartum pain 
Morphine or Buprenorphine for Analgesia Alizadeh et al. 
 
 
 
 
64 Addict Health, Winter & Spring 2015; Vol 7, No 1-2 
 
http://ahj.kmu.ac.ir,    4 April 
management in opioid dependent women. Eur J 
Pain 2012; 16(4): 574-84. 
19. Przeklasa-Muszynska A, Dobrogowski J. 
Transdermal buprenorphine in the treatment of 
cancer and non-cancer pain-the results of 
multicenter studies in Poland. Pharmacol Rep 2011; 
63(4): 935-48. 
20. Zoltie N, Cust MP. Analgesia in the acute abdomen. 
Ann R Coll Surg Engl 1986; 68(4): 209-10. 
21. Finlay I, Scott R, McArdle CS. Prospective  
double-blind comparison of buprenorphine and 
pethidine in ureteric colic. Br Med J (Clin Res Ed) 
1982; 284(6332): 1830-1. 
22. Bullingham RE, McQuay HJ, Moore RA, Weir L. 
An oral buprenorphine and paracetamol 
combination compared with paracetamol alone: a 
single dose double-blind post-operative study. Br J 
Clin Pharmacol 1981; 12(6): 863-7. 
23. Conaghan PG, O'Brien CM, Wilson M, Schofield 
JP. Transdermal buprenorphine plus oral 
paracetamol vs an oral codeine-paracetamol 
combination for osteoarthritis of hip and/or knee: a 
randomised trial. Osteoarthritis Cartilage 2011; 
19(8): 930-8. 
Morphine or Buprenorphine for Analgesia Alizadeh et al. 
 
 
 
1-  	
 	
          ! 
"#  
2- %# 
"# &'() *& +  ,-."  /  / "#(      )0   
3-  
'%#  &'() *& 	
 	
      23
 45   
4-  	
 	
        78)  793('' 
"#  
5- 
 	
      23
 45  ;< 	  
6- %# 
'  &'() *& >+ >+      /   
  :
  "?@ A  
BC  Email: mahmoudi.gh@lums.ac.ir   
 
Addict Health, Winter & Spring 2015; Vol 7, No 1-2 65 
 
http://ahj.kmu.ac.ir,    4 April 
 	 
	    

 	
  	 :    
 	    
  
 	
 
1   
 2  
  3  "# $ %&4  %& (5 
 * " 	 +6  
  
  
"	-.  
:    .
              !"# $  %&' ( )*' + &  
)   ,-. 
" " )/0 1  "1& $
"-  "2  /34 ."5!6   *"  )0("( *0" "789 :
   10 ) " ; ( <      ="&'.  
 : 68    60-20   '        ( )*#9 C  = ;3DE     F 
  ) " 9 ( < .0"5 G0 "2  /34 " $0 *"5 "H )9I 
-9 + "J  )6KL0 )(M  
)  "O0 %1& P: ( QR  
"- & S    S $ Visual analog scale  VAS)&3 P:  ( 
) 
"- &Clinical opioid withdrawal score   COWS ;.*  (1  $6  24   . Q1& ) " ; 9 ( < 

) *"   0 D:9  Q"5    =  65 )X ) *0"  ( "52 )X  ( 3 ()0("( "51  < 

 ( "6 <Y  ;6  ) 
24 "0 ( QR  Q ;.  Z0 .&*"5 "H  2  
-9 (= 
  *SPSS  ;X-9  19
"5.  
 :   "O0 %1& P:6  24  [9"9  *0" Q"5  ) " ; ( < 
73/0 ± 47/4  53/0 ± 67/2  
 
 ' )3   _M  [9"9  *" Q"5  ":69/0 ± 88/5  74/0 ± 68/4 D6 C  *0" Q"5  .  & Da (
0 L0 0  "' S  
"-.  
 :   "7b  F )0("( *0" '  L0 "2  /34     ; ( <  ="&' " )J9 "c
) E .
    0"d Q"J ; ( <   
J   ( $"Ce &C  &09.  
:  
"- & $    )K $; ( <  $*" $*0"  
: !  D? E
 @8) > 8) # +F >9 AF  
BC @ A GHG ' I  A '.  " # # $# "" "
 % # &#'' %(#  :&)! ' *( +( ,. 7K#  '" LM 1394 O7 )2-1( :5-60.  
 :0+1 2137/7/93   :4156 21316/9/93  
  
!"# $	 
